國立高雄大學圖資館 |

Language: English

Back

Biopharmaceutical applied statistics...

Chen, Ding-Geng.

Biopharmaceutical applied statistics symposium.Volume 3,Pharmaceutical applications

Record Type:	Electronic resources : Monograph/item
Title/Author:	Biopharmaceutical applied statistics symposium.edited by Karl E. Peace, Ding-Geng Chen, Sandeep Menon.
other author:	Peace, Karl E.
Published:	Singapore :Springer Singapore :2018.
Description:	xv, 426 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	DrugsTesting
Online resource:	https://doi.org/10.1007/978-981-10-7820-0
ISBN:	9789811078200$q(electronic bk.)

Biopharmaceutical applied statistics symposium.Volume 3,Pharmaceutical applications
Biopharmaceutical applied statistics symposium.Volume 3,Pharmaceutical applications[electronic resource] /edited by Karl E. Peace, Ding-Geng Chen, Sandeep Menon. - Singapore :Springer Singapore :2018. - xv, 426 p. :ill., digital ;24 cm. - ICSA book series in statistics,2199-0980. - ICSA book series in statistics..

Part I: Personalized Medicine -- 1 Targeted Learning of Optimal Individualized Treatment Rules under Cost Constraints -- 2 Uses of Mixture Normal Distribution in Genomics and Otherwise -- 3 Personalized Medicine - Design Considerations -- 4 Adaptive Biomarker Subpopulation and Tumor Type Selection in Phase III Oncology Trials -- 5 High Dimensional Data in Genomics -- Part II: Novel Applications -- 6 Synergy or Additivity - The Importance of Defining the Primary Endpoint -- 7 Full Bayesian Adaptive Dose Finding using Toxicity Probability Interval (TPI) -- 8 Alpha-recycling for the Analyses of Primary and Secondary Endpoints of Clinical Trials -- 9 Expanded Interpretations of Results of Carcinogenicity Studies of Pharmaceuticals -- 1 Clinical Trials in Orphan Drug Development -- 11 Mediation Modeling in Randomized Trials with Non-normal Outcome Variables -- 12 Statistical Considerations in Using Images in Clinical Trials -- 13 Interesting Applications over 30 Years of Consulting -- 14 Uncovering Fraud, Misconduct and Other Data Quality Issues in Clinical Trials -- 15 Development and Evaluation of High Dimensional Prognostic Models -- 16 Design and Analysis of Biosimilar Studies.

This BASS book Series publishes selected high-quality papers reflecting recent advances in the design and biostatistical analysis of biopharmaceutical experiments - particularly biopharmaceutical clinical trials. The papers were selected from invited presentations at the Biopharmaceutical Applied Statistics Symposium (BASS), which was founded by the first Editor in 1994 and has since become the premier international conference in biopharmaceutical statistics. The primary aims of the BASS are: 1) to raise funding to support graduate students in biostatistics programs, and 2) to provide an opportunity for professionals engaged in pharmaceutical drug research and development to share insights into solving the problems they encounter. The BASS book series is initially divided into three volumes addressing: 1) Design of Clinical Trials; 2) Biostatistical Analysis of Clinical Trials; and 3) Pharmaceutical Applications. This book is the third of the 3-volume book series. The topics covered include: Targeted Learning of Optimal Individualized Treatment Rules under Cost Constraints, Uses of Mixture Normal Distribution in Genomics and Otherwise, Personalized Medicine - Design Considerations, Adaptive Biomarker Subpopulation and Tumor Type Selection in Phase III Oncology Trials, High Dimensional Data in Genomics; Synergy or Additivity - The Importance of Defining the Primary Endpoint, Full Bayesian Adaptive Dose Finding Using Toxicity Probability Interval (TPI), Alpha-recycling for the Analyses of Primary and Secondary Endpoints of Clinical Trials, Expanded Interpretations of Results of Carcinogenicity Studies of Pharmaceuticals, Randomized Clinical Trials for Orphan Drug Development, Mediation Modeling in Randomized Trials with Non-normal Outcome Variables, Statistical Considerations in Using Images in Clinical Trials, Interesting Applications over 30 Years of Consulting, Uncovering Fraud, Misconduct and Other Data Quality Issues in Clinical Trials, Development and Evaluation of High Dimensional Prognostic Models, and Design and Analysis of Biosimilar Studies.

ISBN: 9789811078200$q(electronic bk.)

Standard No.: 10.1007/978-981-10-7820-0doiSubjects--Topical Terms:

217216
Drugs
--Testing

LC Class. No.: RS189 / .B567 2018

Dewey Class. No.: 617.040287

Biopharmaceutical applied statistics symposium.Volume 3,Pharmaceutical applications
LDR:04414nmm a2200349 a 4500 001 544000
003 DE-He213
005 20190304133831.0
006 m d
007 cr nn 008maaau
008 190430s2018 si s 0 eng d
020 $a 9789811078200$q(electronic bk.)
020 $a 9789811078194$q(paper)
024 7 $a 10.1007/978-981-10-7820-0 $2 doi
035 $a 978-981-10-7820-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RS189 $b .B567 2018
072 7 $a PBT $2 bicssc
072 7 $a MED090000 $2 bisacsh
072 7 $a PBT $2 thema
072 7 $a MBNS $2 thema
082 0 4 $a 617.040287 $2 23
090 $a RS189 $b .B615 2018
245 0 0 $a Biopharmaceutical applied statistics symposium. $n Volume 3, $p Pharmaceutical applications $h [electronic resource] / $c edited by Karl E. Peace, Ding-Geng Chen, Sandeep Menon.
260 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2018.
300 $a xv, 426 p. : $b ill., digital ; $c 24 cm.
490 1 $a ICSA book series in statistics, $x 2199-0980
505 0 $a Part I: Personalized Medicine -- 1 Targeted Learning of Optimal Individualized Treatment Rules under Cost Constraints -- 2 Uses of Mixture Normal Distribution in Genomics and Otherwise -- 3 Personalized Medicine - Design Considerations -- 4 Adaptive Biomarker Subpopulation and Tumor Type Selection in Phase III Oncology Trials -- 5 High Dimensional Data in Genomics -- Part II: Novel Applications -- 6 Synergy or Additivity - The Importance of Defining the Primary Endpoint -- 7 Full Bayesian Adaptive Dose Finding using Toxicity Probability Interval (TPI) -- 8 Alpha-recycling for the Analyses of Primary and Secondary Endpoints of Clinical Trials -- 9 Expanded Interpretations of Results of Carcinogenicity Studies of Pharmaceuticals -- 1 Clinical Trials in Orphan Drug Development -- 11 Mediation Modeling in Randomized Trials with Non-normal Outcome Variables -- 12 Statistical Considerations in Using Images in Clinical Trials -- 13 Interesting Applications over 30 Years of Consulting -- 14 Uncovering Fraud, Misconduct and Other Data Quality Issues in Clinical Trials -- 15 Development and Evaluation of High Dimensional Prognostic Models -- 16 Design and Analysis of Biosimilar Studies.
520 $a This BASS book Series publishes selected high-quality papers reflecting recent advances in the design and biostatistical analysis of biopharmaceutical experiments - particularly biopharmaceutical clinical trials. The papers were selected from invited presentations at the Biopharmaceutical Applied Statistics Symposium (BASS), which was founded by the first Editor in 1994 and has since become the premier international conference in biopharmaceutical statistics. The primary aims of the BASS are: 1) to raise funding to support graduate students in biostatistics programs, and 2) to provide an opportunity for professionals engaged in pharmaceutical drug research and development to share insights into solving the problems they encounter. The BASS book series is initially divided into three volumes addressing: 1) Design of Clinical Trials; 2) Biostatistical Analysis of Clinical Trials; and 3) Pharmaceutical Applications. This book is the third of the 3-volume book series. The topics covered include: Targeted Learning of Optimal Individualized Treatment Rules under Cost Constraints, Uses of Mixture Normal Distribution in Genomics and Otherwise, Personalized Medicine - Design Considerations, Adaptive Biomarker Subpopulation and Tumor Type Selection in Phase III Oncology Trials, High Dimensional Data in Genomics; Synergy or Additivity - The Importance of Defining the Primary Endpoint, Full Bayesian Adaptive Dose Finding Using Toxicity Probability Interval (TPI), Alpha-recycling for the Analyses of Primary and Secondary Endpoints of Clinical Trials, Expanded Interpretations of Results of Carcinogenicity Studies of Pharmaceuticals, Randomized Clinical Trials for Orphan Drug Development, Mediation Modeling in Randomized Trials with Non-normal Outcome Variables, Statistical Considerations in Using Images in Clinical Trials, Interesting Applications over 30 Years of Consulting, Uncovering Fraud, Misconduct and Other Data Quality Issues in Clinical Trials, Development and Evaluation of High Dimensional Prognostic Models, and Design and Analysis of Biosimilar Studies.
650 0 $a Drugs $x Testing $x Statistical methods $3 217216
650 0 $a Biopharmaceutics $v Congresses. $3 822414
650 1 4 $a Statistics for Life Sciences, Medicine, Health Sciences. $3 274067
650 2 4 $a Biostatistics. $3 339693
700 1 $a Peace, Karl E. $3 776794
700 1 $a Chen, Ding-Geng. $3 487343
700 1 $a Menon, Sandeep. $3 822413
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a ICSA book series in statistics. $3 725077
856 4 0 $u https://doi.org/10.1007/978-981-10-7820-0
950 $a Mathematics and Statistics (Springer-11649)